Recent News

• 08.20.2025 - Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update
• 08.19.2025 - Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call
• 08.01.2025 - Vivos Therapeutics Adds to Management Team to Support Expansion and Growth
• 07.21.2025 - Two nights of home polysomnography in healthy 7- 14-year-old children – Feasibility and intraindividual variability
• 07.21.2025 - Use of the Complete Airway Repositioning and Expansion (CARE) approach in 220 patients with Obstructive Sleep Apnea (OSA): A retrospective cohort study
• 07.21.2025 - Multicenter clinical trial for the treatment of obstructive sleep apnea with a non‑permanent orthodontic intraoral device in children
• 07.21.2025 - Improved diagnostic accuracy for pediatric obstructive sleep apnea using an out-of-center sleep test
• 07.16.2025 - What Is Moderate OSA?
• 06.18.2025 - What Is Mild OSA?
• 06.11.2025 - Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada

Recent Filings

• 08.19.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
• 07.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 06.20.2025 - 3 Initial statement of beneficial ownership of securities
• 06.16.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 06.13.2025 - EX-99.1 EX-99.1
• 06.13.2025 - 8-K Current report
• 06.06.2025 - 8-K Current report
• 05.23.2025 - 8-K Current report